Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
State-of-the-Art Molecular and Translational Medicine in Japan
share announcement

State-of-the-Art Molecular and Translational Medicine in Japan

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 651

Special Issue Editor

Dr. Takemichi Fukasawa

E-Mail Website
Guest Editor
Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
Interests: systemic sclerosis; Psoriasis; atopic dermatitis; myositis; sle; vasculitis; b cells; T cells
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, molecular and translational research has been carried out on various diseases. Many biologics targeting inflammatory cytokines and molecularly targeted drugs such as JAK inhibitors have emerged. The mechanisms of action and research on these drugs are advancing at a tremendous pace.

This Special Issue compiles cutting-edge research from Japan, focusing on state-of-the-art information on various diseases from a molecular viewpoint. We warmly welcome research and review articles concerning a variety of factors relating to skin diseases, including their genetic/epigenetic regulation, therapy, and prevention. In this Special Issue, we aim to present the latest information on such diseases, from their basic mechanisms to therapies.

Dr. Takemichi Fukasawa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular and translational research
  • targeting inflammatory cytokines
  • targeted drugs
  • skin diseases
  • basic mechanisms
  • novel therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

8 pages, 1230 KiB  
Communication
Topical Application of OJI-204 Alleviates Skin Dryness, Dry Skin-Induced Itch, and Mechanical Alloknesis
by Sumika Toyama, Tomoya Nakamura, Mitsutoshi Tominaga and Kenji Takamori
Biomedicines 2025, 13(3), 556; https://doi.org/10.3390/biomedicines13030556 - 21 Feb 2025
Viewed by 484
Abstract
Background/Objectives: The skin is an important barrier that protects against invasion by foreign substances and retains water in the body. Several skin diseases involve dry skin due to a disrupted skin barrier, and most skin diseases that appear on dry skin are [...] Read more.
Background/Objectives: The skin is an important barrier that protects against invasion by foreign substances and retains water in the body. Several skin diseases involve dry skin due to a disrupted skin barrier, and most skin diseases that appear on dry skin are accompanied by itch. Dry skin-induced itch and mechanical alloknesis reduce quality of life. Sulfated hemicellulose (i.e., pentosan polysulfate sodium), similar to heparin, is a compound belonging to the sulfated polysaccharide family; however, in contrast to heparin, it is derived from plant materials. We herein investigate the effects of the topical application of OJI-204, a sulfated hemicellulose made by purifying and chemically synthesizing hemicellulose, on dry skin in a mouse model. Methods: The mouse model of dry skin was generated using a mixture of acetone and ether with water. Either OJI-204 (3% or 10%) or 0.3% heparinoid, PBS (control), was applied twice a day to the acetone and diethyl ether/water (AEW)-treated area. The degree of skin dryness was evaluated by measuring transepidermal water loss and stratum corneum hydration. Scratching behavior was recorded the day before AEW treatment and the day after the final day, and an alloknesis assay was performed on the day after the final day. Results: We found that 3% or 10% OJI-204 attenuated dry skin conditions (erythema/hemorrhage, scarring/dryness, edema, and excoriation/erosion) and itchiness more effectively than 0.3% heparinoid. Furthermore, the degree of dryness improved to the same degree as that with heparinoid. OJI-204 also significantly reduced dry skin-induced spontaneous itch and mechanical alloknesis. Conclusions: These results suggest the potential of OJI-204 as a therapeutic or preventive agent for dry skin. Full article
(This article belongs to the Special Issue State-of-the-Art Molecular and Translational Medicine in Japan)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop